<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503451</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589B2110</org_study_id>
    <nct_id>NCT00503451</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase IB, Study to Investigate the Effect of Ketoconazole, a CYP3A4 Inhibitor, on Oral LBH589 and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary purpose of this open-label study is to investigate the interaction of&#xD;
      ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid&#xD;
      tumors. The extension phase of the study will evaluate the safety and efficacy of LBH589 in&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of LBH589 in the blood on days 1, 5, 8, 9 and 10 of first cycle</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerability and efficacy of oral LBH589 throughout the study</measure>
    <time_frame>at least every 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>LBH589</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LBH589</intervention_name>
    <arm_group_label>LBH589</arm_group_label>
    <other_name>Panobinostat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients with histologically confirmed solid tumors or non-Hodgkin's lymphoma with&#xD;
             progression on prior standard therapies.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2&#xD;
&#xD;
          -  Adequate kidney function and laboratory values&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients who have received chemotherapy, any investigational drug, undergone major&#xD;
             surgery, or received wide field radiotherapy less than 4 weeks ago&#xD;
&#xD;
          -  Patients who had a heart attack or have unstable angina within past 6 months&#xD;
&#xD;
          -  Heart disease including congestive heart failure and uncontrolled high blood pressure&#xD;
&#xD;
          -  Liver disease, abnormal gastrointestinal (GI) function or ongoing diarrhea&#xD;
&#xD;
          -  Use of any anti-cancer therapy, including radiation therapy, or certain drugs while on&#xD;
             study&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding.&#xD;
&#xD;
        Other protocol inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=4102</url>
    <description>Results for CLBH589B2110 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced cancer</keyword>
  <keyword>solid tumors</keyword>
  <keyword>lymphoma</keyword>
  <keyword>HDAC</keyword>
  <keyword>LBH589</keyword>
  <keyword>adults</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

